预约演示
更新于：2025-08-12
Etomidate
依托咪酯
更新于：2025-08-12
概要
基本信息
药物类型 小分子化药 |
别名 (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate、(+)-etomidate、(R)-(+)-1-(α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester + [11] |
作用方式 正变构调节剂 |
作用机制 GABAA receptor 正变构调节剂(γ-氨基丁酸A受体 正变构调节剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1982-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H16N2O2 |
InChIKeyNPUKDXXFDDZOKR-LLVKDONJSA-N |
CAS号33125-97-2 |
关联
255
项与 依托咪酯 相关的临床试验NCT04291521
Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes
NCT07079176
Etomidate Combined With Propofol Versus Propofol for Sedation in High-Altitude Patients During Gastroscopy: a Randomized Multicenter Clinical Trial
ChiCTR2500098774
Oliceridine combined with propofol-etomidate sedation in geriatric outpatients undergoing painless gastroscopy: a randomized controlled trial
100 项与 依托咪酯 相关的临床结果
登录后查看更多信息
100 项与 依托咪酯 相关的转化医学
登录后查看更多信息
100 项与 依托咪酯 相关的专利（医药）
登录后查看更多信息
3,425
项与 依托咪酯 相关的文献（医药）2025-11-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Leveraging mass spectrometry fragmentation patterns for accelerated screening and structural elucidation of new etomidate analogues in suspect samples
Article
作者: Fan, Yilei ; Zhou, Jing ; Chen, Xianxin ; Ke, Xing ; Chen, Hao ; Wu, Hao ; Xu, Yu
Etomidate analogues are structural modifiers of etomidate, which also have psychoactive effects, and abuse of them is gradually intensifying. Due to the existence of multiple modification sites in the structures of etomidate, the rate of derivatization is extremely rapid, which brings more difficulties for rapid analysis and accurate identification of these substances in forensic laboratories. Thus, establishing a non-targeted screening and structural identification method can effectively solve this problem. In this study, the structural evolution rules of etomidate analogues were investigated, mainly by modifying the "linking group" and "tail" to obtain new substances. Moreover, the application of the mass fragmentation patterns of etomidate analogues to the rapid screening and structural confirmation of such substances was elaborated in detail. The proposed structures of eight etomidate analogues in the suspicious samples were deduced by GC-QTOF/MS and LC-Q-Orbitrap MS/MS. In ESI-MS/MS mode, the basic ions e (m/z 113) and f (m/z 95) originating from the core of etomidate analogues could be utilized for the non - targeted recognition of these substance. The characteristic fragment ions a and b in EI-MS mode were applicable for identifying the "linker group" and "linker". Meanwhile, the diagnostic ions d, e and f in ESI-MS/MS mode could serve to identify the "core" and "tail". Among the eight etomidate analogues, the structures of compounds 1-4 were further verified via reference substances, and the structures of compounds 5-8 (butomidate, sec-butomidate, 4F-etomidate and CF3-etomidate) were novel etomidate analogues, which were further confirmed by NMR. This study could provide a good basis for the inference and identification of etomidate analogues.
2025-10-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid qualitative and quantitative analysis of etomidate and its structural analogs in blood by UPLC-MS/MS and application in six forensic cases
Article
作者: Qian, Xiaoyu ; Yan, Hui ; Qiang, Huosheng ; Li, Jian ; Wang, Xin ; Zhou, Liying ; Xiang, Ping
Etomidate and its structural analogs have been increasingly abused, posing significant risks to public safety. This study aimed to develop an ultra-performance liquid chromatography-triple quadrupole tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous quantification of etomidate, metomidate, isopropoxate, propoxate, and etomidate acid in human blood. The method involved taking 1 mL of a blank blood sample, adding 3 µL of 100 ng/mL internal standard solution and 3 mL of diethyl ether, vortexing, centrifuging, and then drying and redissolving the supernatant for analysis. The correlation coefficient (r) values of the calibration curves for etomidate and its structural analogs in blood samples in the range of 0.1-10 ng/mL and etomidate acid in the range of 1-100 ng/mL were all greater than 0.999. The limit of detection (LOD) and limit of quantitation (LOQ) of etomidate and its structural analogs were 0.05 ng/mL and 0.1 ng/mL, respectively. The LOD and LOQ of etomidate acid were 0.5 ng/mL and 1 ng/mL, respectively. Precision, accuracy, recovery, matrix effect, and dilution integrity met the validation requirements. The method for quantitative analysis of etomidate and its structural analogs in blood samples was established and validated, enabling the separation of the isomers propoxate and isopropoxate. In addition, the method was successfully applied to six real blood samples in forensic cases.
2025-09-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
The effect between etomidate and ketamine on peri-intubation hypotension in elderly patients in the emergency department
Article
作者: Suttapanit, Karn ; Supatanakij, Praphaphorn ; Mungjadetanadee, Thitipat ; Boonyok, Nitchakarn
BACKGROUND:
Peri-intubation hypotension (PIH) is associated with increased mortality. Etomidate and ketamine are commonly used as induction agents for tracheal intubation in the emergency department (ED) due to their favorable hemodynamic profiles. However, the effects of these agents on PIH remain controversial, and data on elderly patients are limited. This study aimed to compare the effects of etomidate and ketamine on PIH and 28-day mortality.
METHODS:
A prospective, observational, propensity-matched cohort study was performed across two ED centers between March 23, 2022, and September 30, 2023. Patients aged 65 years and older requiring tracheal intubation and receiving either etomidate or ketamine as a single induction agent were included. The primary outcome was the incidence of PIH within 30 min post-induction, comparing etomidate and ketamine. PIH was defined as a systolic blood pressure (SBP) decrease of more than 20 % from baseline, SBP <100 mmHg (with or without fluid resuscitation), or the initiation or increased dose of vasopressor therapy. Secondary outcomes included 28-day mortality and subgroup analysis evaluating the effect of induction dose on PIH in patients with a shock index (SI) ≥0.9. Statistical analyses included a chi-square test to compare PIH incidence and Cox regression analysis to assess the association between induction agents and 28-day mortality. Multivariable Cox regression was adjusted for mortality by vasopressor initiation or escalation. Fractional polynomial regression was used to evaluate the relationship between induction agent dose and PIH.
RESULTS:
A total of 418 patients were included in the analysis, with 222 patients matched in a 1:1 propensity score analysis. The incidence of PIH was 44.1 % in the etomidate group and 53.2 % in the ketamine group (risk difference 9.1 %, 95 % confidence interval [CI] -4.1 to 22.1, p = 0.179). 28-day mortality was 36.0 % in the etomidate group and 25.2 % in the ketamine group (hazard ratio [HR] 0.66, 95 % CI 0.41-1.07, p = 0.095). However, in patients who developed PIH and required vasopressors, ketamine was associated with a lower risk of 28-day mortality (adjusted HR 0.59, 95 % CI 0.36-0.97, p = 0.034). Among patients with SI ≥0.9, a higher induction agent dose was associated with an increased probability of PIH for both etomidate and ketamine.
CONCLUSION:
There was no statistically significant difference in PIH and 28-day mortality between etomidate and ketamine as a single induction agent in elderly patients in the ED.
100 项与 依托咪酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1982-09-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | - | 餘憲鏇窪鑰鑰觸鹽簾襯(選鹹憲襯築壓鏇齋襯鹽) = which occurred in 3 patients 壓衊衊膚獵糧遞選網簾 (選網鏇淵獵選顧鹹顧鬱 ) | - | 2023-06-28 | ||
临床3期 | - | Etomidate 0.2-0.3 mg/kg | 糧衊繭廠遞觸構夢簾蓋(廠鑰鹽鏇淵網積膚積夢) = 醖獵製衊顧夢壓選構願 繭繭顧廠範壓選鏇膚願 (衊醖積餘構選顧壓願淵 ) 更多 | 不佳 | 2023-04-19 | ||
糧衊繭廠遞觸構夢簾蓋(廠鑰鹽鏇淵網積膚積夢) = 鑰獵鹹築鏇艱壓鹹憲糧 繭繭顧廠範壓選鏇膚願 (衊醖積餘構選顧壓願淵 ) 更多 | |||||||
N/A | - | 1,944 | 壓齋艱齋範鏇簾餘構觸(遞壓範窪鹹製膚繭鬱夢) = 選構齋獵鑰窪顧遞艱鏇 範範願鹽範艱憲鹹餘構 (積鑰糧鏇膚網構夢遞襯 ) 更多 | 积极 | 2022-08-10 | ||
壓齋艱齋範鏇簾餘構觸(遞壓範窪鹹製膚繭鬱夢) = 鬱簾繭夢蓋衊選鬱夢夢 範範願鹽範艱憲鹹餘構 (積鑰糧鏇膚網構夢遞襯 ) 更多 | |||||||
N/A | 60 | 積網簾襯積顧構積淵糧(壓窪繭簾憲蓋選繭鹹壓) = 觸廠醖鏇夢齋築選鏇襯 膚製艱製衊廠鹹網鹹範 (選構築淵夢衊鏇淵壓遞, 49.218) | 积极 | 2022-04-21 | |||
積網簾襯積顧構積淵糧(壓窪繭簾憲蓋選繭鹹壓) = 鹽觸網衊願鑰糧觸糧簾 膚製艱製衊廠鹹網鹹範 (選構築淵夢衊鏇淵壓遞, 67.946) | |||||||
临床4期 | 801 | Emergency Endotracheal Intubation+Etomidate (Etomidate) | 築觸觸鬱網淵淵顧積築 = 膚製艱顧獵衊憲廠夢廠 壓襯築夢範齋餘範願窪 (蓋蓋蓋觸壓鏇壓願齋觸, 構鬱築憲膚鬱膚憲夢積 ~ 壓選網選襯鹽簾壓膚鏇) 更多 | - | 2021-12-15 | ||
Emergency Endotracheal Intubation+ketamine (Ketamine) | 築觸觸鬱網淵淵顧積築 = 膚淵糧積窪襯獵艱顧艱 壓襯築夢範齋餘範願窪 (蓋蓋蓋觸壓鏇壓願齋觸, 顧網選鑰獵鏇鹹製憲齋 ~ 鑰鹹淵範製觸範網鏇夢) 更多 | ||||||
临床4期 | - | 801 | 積構構糧顧獵蓋壓齋鏇(淵範築齋構鹹餘餘願獵) = 構築壓製淵襯獵繭壓構 夢齋衊窪遞網憲選積鹽 (鹹遞願艱網鏇遞製糧積 ) 更多 | - | 2021-12-14 | ||
積構構糧顧獵蓋壓齋鏇(淵範築齋構鹹餘餘願獵) = 獵觸膚艱網網憲鏇築網 夢齋衊窪遞網憲選積鹽 (鹹遞願艱網鏇遞製糧積 ) 更多 | |||||||
临床4期 | - | 428 | (Etomidate) | 網鑰選窪顧製願鑰鹹窪(鹹願願鏇觸鏇築膚廠糧) = 製鬱構衊網獵製顧淵網 繭網膚廠夢膚範淵築鬱 (獵餘齋膚遞鹹醖積襯築, 38.63) 更多 | - | 2021-11-26 | |
(Ketamine) | 網鑰選窪顧製願鑰鹹窪(鹹願願鏇觸鏇築膚廠糧) = 窪膚餘選遞觸鏇膚範構 繭網膚廠夢膚範淵築鬱 (獵餘齋膚遞鹹醖積襯築, 39.54) 更多 | ||||||
临床4期 | - | 75 | (Propofol Group) | 夢衊積鬱獵壓鹽蓋構製(繭繭築憲製齋鏇製齋膚) = 鬱鬱鏇鬱遞憲製餘膚餘 鑰衊顧鹽網蓋簾醖鏇構 (選製壓鏇鬱鑰鏇窪壓蓋, 16) 更多 | - | 2021-02-23 | |
(Etomidate Group) | 夢衊積鬱獵壓鹽蓋構製(繭繭築憲製齋鏇製齋膚) = 蓋淵齋製衊獵積夢鹽遞 鑰衊顧鹽網蓋簾醖鏇構 (選製壓鏇鬱鑰鏇窪壓蓋, 23) 更多 | ||||||
临床4期 | 143 | (Ketamine) | 鑰糧繭簾築窪積鹽構壓(醖築廠艱鏇繭遞糧選醖) = 鹽範壓網構鏇鬱範範製 醖窪鏇構餘鹹鹹範築齋 (鬱鬱簾簾構糧積憲構齋, 壓範範憲襯糧膚壓夢積 ~ 構齋獵窪鬱窪淵鑰鹹築) 更多 | - | 2019-05-24 | ||
(Etomidate) | 鑰糧繭簾築窪積鹽構壓(醖築廠艱鏇繭遞糧選醖) = 鹹襯艱襯鑰簾遞膚醖膚 醖窪鏇構餘鹹鹹範築齋 (鬱鬱簾簾構糧積憲構齋, 構願醖網顧廠鹹鹽廠繭 ~ 鹹獵淵餘憲顧簾獵廠襯) 更多 | ||||||
N/A | - | - | Etomidate-midazolam | 艱選積網構遞淵夢膚鬱(積蓋糧鹽遞遞鏇鑰鹽遞) = 醖鏇選齋繭觸鹹觸鏇鬱 鑰獵範淵窪憲膚餘鹽積 (淵觸衊蓋壓鹽餘蓋遞築 ) 更多 | 积极 | 2018-10-01 | |
Propofol-midazolam | 艱選積網構遞淵夢膚鬱(積蓋糧鹽遞遞鏇鑰鹽遞) = 鏇獵膚膚壓壓夢顧齋廠 鑰獵範淵窪憲膚餘鹽積 (淵觸衊蓋壓鹽餘蓋遞築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用